
LINKÖPING, Sweden, January 22, 2024 –The 2025 EASL-SLD Summit – which runs from January 23-25th in beautiful Estoril, Portugal – brings together healthcare professionals and researchers from across the steatotic liver disease field, blending clinical education with the latest updates in liver disease research in order to help drive innovation forward.
AMRA is especially excited to be part of a collaborative effort driven by our colleagues at Linköping University (LiU), for which results will be presented at the summit. The study – a part of the Research Network For The Study of Ectopic Fat Deposition led by Dr. Mattias Ekstedt – revealed that adverse muscle composition is associated with an increased risk of future adverse events in patients investigated for chronic liver disease, even when adjusting for traditional risk factors. Read about the network here: https://shorturl.at/m5KjO
“Muscle atrophy is devious since it progresses without symptoms. Our results show that we can easily quantify our patients muscle health based on an MRI examination, and this provides important prognostic information” says Dr. Ekstedt, Deputy Head of the Department of Health, Medicine and Caring Sciences at LiU.
You can learn more about our study, titled “Muscle Composition Predicts Adverse Outcomes in Chronic Liver Disease: A 5-Year Follow-Up Study”, during ePoster Session 6, which runs from 13.45-14.15 on January 25.
If you want to learn more about how AMRA’s biomarkers are uncovering the role of muscle health in liver disease and beyond, make sure to connect with us by emailing us at info@amramedical.com.
About AMRA Medical
AMRA Medical is a health informatics and precision medicine company that is pioneering body composition analysis, providing cutting-edge solutions to advance both clinical research and patient care initiatives. AMRA’s gold-standard technology delivers multiple fat and muscle biomarkers – derived simply from rapid whole-body MRI scans. AMRA is committed to driving transformative care and simplifying vital decision-making in both research and clinical care settings by offering support services via their innovative platform.
Follow AMRA on LinkedIn for the latest updates in fat distribution and muscle composition assessments in disease research.
MEDIA CONTACT INFORMATION
AMRA Medical
Marie Börjesson, VP Brand & Marketing
0046 70 628 1977
marie.borjesson@amramedical.com